834 related articles for article (PubMed ID: 15879128)
1. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
2. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
3. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
[TBL] [Abstract][Full Text] [Related]
4. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
[TBL] [Abstract][Full Text] [Related]
5. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
Rice J; Elliott T; Buchan S; Stevenson FK
J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
[TBL] [Abstract][Full Text] [Related]
6. Enhanced priming of multispecific, murine CD8+ T cell responses by DNA vaccines expressing stress protein-binding polytope peptides.
Schirmbeck R; Fissolo N; Chaplin P; Reimann J
J Immunol; 2003 Aug; 171(3):1240-6. PubMed ID: 12874211
[TBL] [Abstract][Full Text] [Related]
7. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
Bråve A; Hallengärd D; Gudmundsdotter L; Stout R; Walters R; Wahren B; Hallermalm K
Vaccine; 2009 Jun; 27(28):3692-6. PubMed ID: 19428161
[TBL] [Abstract][Full Text] [Related]
8. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols.
Palmowski MJ; Choi EM; Hermans IF; Gilbert SC; Chen JL; Gileadi U; Salio M; Van Pel A; Man S; Bonin E; Liljestrom P; Dunbar PR; Cerundolo V
J Immunol; 2002 May; 168(9):4391-8. PubMed ID: 11970981
[TBL] [Abstract][Full Text] [Related]
9. Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells.
Radcliffe JN; Roddick JS; Friedmann PS; Stevenson FK; Thirdborough SM
J Immunol; 2006 Nov; 177(10):6626-33. PubMed ID: 17082574
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus.
Takeda J; Sato Y; Kiyosawa H; Mori T; Yokoya S; Irisawa A; Miyata M; Obara K; Fujita T; Suzuki T; Kasukawa R; Wanaka A
Cell Immunol; 2000 Aug; 204(1):11-8. PubMed ID: 11006013
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
12. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
13. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
14. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.
Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P
J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity.
Casares N; Lasarte JJ; de Cerio AL; Sarobe P; Ruiz M; Melero I; Prieto J; Borrás-Cuesta F
Eur J Immunol; 2001 Jun; 31(6):1780-9. PubMed ID: 11385623
[TBL] [Abstract][Full Text] [Related]
16. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
17. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
[TBL] [Abstract][Full Text] [Related]
18. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of protective efficacy induced by different heterologous prime-boost strategies encoding triosephosphate isomerase against Schistosoma japonicum in mice.
Dai Y; Zhao S; Tang J; Xing Y; Qu G; Dai J; Jin X; Wang X
Parasit Vectors; 2017 Feb; 10(1):111. PubMed ID: 28241779
[TBL] [Abstract][Full Text] [Related]
20. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.
Sailaja G; Husain S; Nayak BP; Jabbar AM
J Immunol; 2003 Mar; 170(5):2496-507. PubMed ID: 12594275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
